European CHMP Recommends Approval for Four Celltrion Biosimilars

Celltrion announced on Dec. 16 that it had received a recommendation for approval from the Committee for Medicinal Products for Human Use...
1 day ago
from: Businesskorea

Aflibercept, Biosimilar, Celltrion, Committee for Medicinal Products for Human Use, European Medicines Agency, European Union, Marketing authorisation, Tocilizumab

More about this

- Celltrion receives CHMP’s positive opinion for biosimilars
Celltrion Inc. announced Monday that its four biosimilars received a recommendation for approval from the Committee for Medicinal Products...
from: 매일경제

- Celltrion biosimilars recommended for EU approval
Celltrion received recommendations of approval for four of his biosimilar products by the European Medicines Agency's screening board.
from: Korea JoongAng Daily

- Celltrion Secures European Approval Recommendations for Four Biosimilars
On December 16, Celltrion announced that it has received recommendations for European market authorization from the Committee for Medicinal...
from: Korea IT Times

- Celltrion has been informed by the European Medicines Agency (EMA) that ACTEMRA (European brand name..
Aptozma is a biosimilar of Actemra, an original drug used to treat autoimmune diseases such as rheumatoid arthritis (RA) and giant cell...
from: 매일경제